Yu-Jet Co., Ltd. is a Taiwan-based biopharmaceutical company dedicated to the development of treatments for rare diseases.

The company integrates drug formulation development, clinical research, and Clinical Decision Support System (CDSS) technologies, building on three pillars — Drug R&D × Precision Medicine × Clinical Application — to bring local innovations to the global stage.

• Mission： Patient-centric innovation to make rare disease treatments more accessible and affordable.
• Vision： To build a globally recognized precision medicine brand for rare diseases originating from Taiwan.

Yu-Jet’s core strategy centers on “Innovation in Rare Disease Treatment and Integration of Precision Medicine.”

We have established a complete value chain spanning from R&D → clinical → post-marketing surveillance.

• Founder’s Philosophy

  “Our mission is to deliver affordable, effective, and globally competitive treatments for rare diseases — starting from Taiwan and reaching the world.”
  — Founder and General Manager, Jeff Chen

• Strategic Focus：
  • Drug Repurposing：Rapidly repurpose known molecules into new applications to shorten development timelines.
  • Global Regulatory Integration：Simultaneously align with FDA, EMA, and TFDA.
  • Precision Medicine Platform：Combine EEG and pressure-sensing devices with CDSS for precise therapy guidance.
  • Cross-Sector Collaboration：Link industry, government, and academia to strengthen Taiwan’s innovation ecosystem.

• Clinically Driven Innovation
  

  Yu-Jet focuses on addressing real clinical needs, with an emphasis on rare and high-value niche markets.

  Through close collaboration with clinicians, we rapidly transform clinical challenges into commercially viable therapeutic solutions — ensuring efficient translation from bench to bedside.

• Integrated Drug & Decision Support Solutions
  

  eyond drug development, Yu-Jet builds a “Diagnosis × Therapy × Data” ecosystem.

  From screening and diagnosis to treatment, we deliver next-generation precision-medicine solutions that enhance clinical outcomes and patient care.

• Cross-Functional Collaboration
  

  By uniting leading experts from medicine, pharmaceuticals, data science, and AI, Yu-Jet has established a multidisciplinary innovation platform.

  This integration drives Taiwan’s biomedical advancement and expands our global footprint.